RE:RE:RE:New Corporate Presentation Out Not sure what you are talking about. You were quoting a remark by JFM not me. I am disappointed we have not heard at least one piece of positive info yet from the trial but I am not freaking out. As I noted, other large shareholders I know who met with management yesterday came away feeling very good about the potential of TH-1902 and I they are not idiots. So, if we have had this much patience all ready, I suppose we can summon up just a little more.
SABBOBCAT wrote: Wow, i can't recall SPCEO being this close to packing it in before. Is this a puke on shoes moment beofre the rip, or is this a reality check that its time to get off the treadmill? Only time will tell.
jfm1330 wrote: Finally it was pointless to hope for something different. All we got was old Thera doing its usual stuff. This phase Ib is on track to be as much outside timelines given as the phase Ia was, which means late by a lot.
We can analyse what they say or don't say all we want, the reality is that we have no certainty about anything on real patients that can without a doubt link TH1902 to efficacy or proof of concept. They reiterated their 11% "level" of free docetaxel claim in the PR without specifying what this 11% clearly means. In this statement, "level" can mean different things depending on the nature of the measurement it is based on.
Honestly, it is incredible that 18 months after the start of the phase I we still cannot know for sure if the concept works and the whole trial is awfully slow. Maybe my expectations were not realistic, but if it's the case the whole trial process was very poorly explained by the company because since the fall of 2021 they were leading us to expect a great news on efficacy in a relatively near future, but this news never came and they are, again, pushing the timeframe. Maybe Levesque was blurting stuff in presentation without understanding what he was talking about, but the least I can say is that he was off marks since the beginning when he talked about timelines for this trial.
He talked often about how preclinical data about TH1902 was seen by outside people as "stunning". Then, all he said after that led to think that these "stunning" preclinical results would quickly lead to clear efficacy in humans and an easy proof of concept. 18 months after the start of the trial, we are down to very little. We are reduce to try to interpret stuff they say, their tone, participation to conferences or presentations, etc... but nothing of substance. Sorry, if they would have something of value in their hands, they would share it. They need it to raise money under acceptable terms. Honestly, I am close to giving up. Look at NASH, they went from very upbeat to close to zero, unwilling to declare the program dead. It now looks similar with TH1902. They still say all is on track, until the day they will tell us it's not. Also, why are they reassuring big investors in private after the conference call, while they are letting the little ones like me in the dark with the conference call? Anyway, if they did not disclose any new informations to these investors, how can they be reassured? Is the tone of the convesation again? That's what we are down to, looking at the tone of the CEO? Is he in a good day for BS or is he also tired of it? That's what we have left to decide to sell or not?